Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167481 | 0.87 | HCRTR1 (0.34) | HCRTR1HCRTR2MAPTCYP11B1HTT | |
| SCHEMBL291192 | 0.85 | HCRTR1 (0.37) | HCRTR1HCRTR2MAPTHTTSMN1; SMN2 | |
| SCHEMBL10167484 | 0.84 | HCRTR1 (0.35) | HCRTR1HCRTR2MAPTHTTSMN1; SMN2 | |
| SCHEMBL10167491 | 0.83 | LMNA (0.40) | HCRTR1HCRTR2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL351412 | 0.82 | PDE4A (0.34) | HCRTR1HCRTR2MAPTHTTSMN1; SMN2 | |
| SCHEMBL10167486 | 0.82 | HCRTR1 (0.33) | HCRTR1HCRTR2MAPTLMNA | |
| SCHEMBL355401 | 0.82 | HPGD (0.34) | HCRTR1HCRTR2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10207038 | 0.80 | MAPT (0.31) | MAPTHTTSMN1; SMN2GRM5 | |
| SCHEMBL10167558 | 0.80 | MAPT (0.49) | HCRTR1HCRTR2MAPTALDH1A1 | |
| SCHEMBL10167454 | 0.79 | POLB (0.35) | MAPTHTTGRM5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119568-B2 | 3-amino-1,2-benzisothiazole compounds for combating animal pest II | BASF SE (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100009848-A1 | 3-Amino-1,2-Benzisothiazole Compounds for Combating Animal Pest II | BASF SE (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2008090048-A2 | 3-AMINO-1,2-BENZISOTHIAZOLE COMPOUNDS FOR COMBATING ANIMAL PEST II | BASF SE (DE) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009848-A1 | 3-Amino-1,2-Benzisothiazole Compounds for Combating Animal Pest II | BPNT1, BCAT1, TGFBR1 | HCRTR1 1004/4885HCRTR2 2047/4885MAPT 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.